Screener / SEC EDGAR /CIK 0000730272 /10-K filed Feb 26, 2026, compared with Mar 14, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Biotechnology

Repligen Corp RGEN

Compare with peers Embed
CEO pay, fiscal year to Dec 31, 2025

Mr. Loeillot was paid $6.1M as reported, $8.7M at the share price

Proxy (DEF 14A)
CEO pay, as reported $6.1M salary, bonus and awards at grant value
CEO pay, actually paid $8.7M awards valued at the share price
$100 in the shares became $86 peer group: $125
CEO pay, 5 years $57.0M down 21% while net income fell 62%

Did pay move with results?

Each line is 100 in 2021 · pay versus performance table, proxy (DEF 14A)

-50050100150 20212022202320242025 CEO pay, 2021: 100CEO pay, 2022: -49CEO pay, 2023: 29CEO pay, 2024: 21CEO pay, 2025: 30 CEO pay 30 Net income, 2021: 100Net income, 2022: 145Net income, 2023: 33Net income, 2024: -20Net income, 2025: 38 Net income 38 $100 invested, 2021: 100$100 invested, 2022: 64$100 invested, 2023: 68$100 invested, 2024: 54$100 invested, 2025: 30 $100 invested 30

When the pay line climbs faster than net income and the $100 line, pay rose more than results did; when it falls with them, it followed them. "Actually paid" re-values stock awards at the share price, so it moves with the stock. Numbers as the company tagged them in its proxy.

Pay against results, year by year

Pay versus performance · proxy, filed Apr 2, 2026

Fiscal year toCEOCEO pay (reported) CEO pay (actually paid) $100 became
Dec 31, 2025Mr. Loeillot $6.1M$8.7M $86
Dec 31, 2024Mr. Loeillot $27.5M$6.0M $156
Aug 31, 2024 part yearMr. Hunt $20.3M- -
Dec 31, 2023Mr. Hunt $7.9M$8.2M $194
Dec 31, 2022Mr. Hunt $7.7M-$14.0M $183
Dec 31, 2021Mr. Hunt $7.8M$28.8M $286

Pay versus performance table of the proxy statement (DEF 14A) filed Apr 2, 2026, as tagged by the company in XBRL. Open the proxy

Pay against free cash flow per share, at peers

Change over the years each proxy covers · pay versus performance table, DEF 14A, and 10-K XBRL

CEO pay, as reported Free cash flow per share » runs past the edge. Pay is salary, bonus and awards at grant value. FCF per share is cash from operations less capital spending, over diluted shares, from the 10-K of the same fiscal year.

RGEN: CEO pay fell 21% from FY2021 to FY2025 ($7.8M to $6.1M), while free cash flow per share rose 83% ($906.80 to $1660.12). Open the proxy

Sources

The pay versus performance table of the latest proxy statement, as the company tagged it in XBRL.

Also

Cash & buybacks: what the company did with its cash in the same years.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/RGEN/export.csv") into a cell.

Next:Crypto holdings
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.